{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:14:12Z","timestamp":1792084452259,"version":"4.4.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Invasive fungal infections (IFI) is an important contributing factor in morbidity and mortality of immunocompromised and critically ill patients. Although the therapeutic effects of these drugs on IFI have been well documented, the long-term use of antifungal agents has raised concerns about drug tolerability and treatment-related toxicity risks.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We searched articles published before June 30, 2020 in four electronic databases: Web of Science, Cochrane Library, embase and PubMed.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> 66 trials were determined to meet our inclusion criteria, providing data on 18,230 participants. We sorted out 23 AEs by system organ classes and six laboratory AEs, 13 of these were used to construct 13 network meta-analyses. Compared with LAmB, anidulafungin, caspofungin, micafungin, fluconazole, and posaconazole had a significantly low incidence of discontinuation of therapy due to AEs (OR = 0.24 (0.09,0.65), 0.24 (0.13,0.43), 0.32 (0.19,0.52), 0.38 (0.23,0.62) and 0.35 (0.17,0.69), respectively).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> We found that echinocandins are the most tolerated antifungal agents with high safety. The AEs of triazole drugs are mainly concentrated on the increase in liver enzymes, nervous system disorders, especially visual disorders, gastrointestinal disorders, and cardiac diseases. LAmB is the least tolerated and has the most abundant AEs.<\/jats:p>","DOI":"10.3389\/fphar.2021.697330","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T04:52:29Z","timestamp":1635483149000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["Adverse Effects Associated With Currently Commonly Used Antifungal Agents: A Network Meta-Analysis and Systematic Review"],"prefix":"10.3389","volume":"12","author":[{"given":"Yan-Li","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Jian","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Chun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo-Lan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/13993003.01159-2018","article-title":"A Randomised Trial of Voriconazole and Prednisolone Monotherapy in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma","volume":"52","author":"Agarwal","year":"2018","journal-title":"Eur. Respir. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/jac\/dkx44810.1093\/jac\/dky013","article-title":"We Can Do Better: a Fresh Look at Echinocandin Dosing","volume":"73","author":"Bader","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2174\/1872213x13666190919162414","article-title":"Skin Allergy to Azole Antifungal Agents for Systemic Use: A Review of the Literature","volume":"13","author":"Calogiuri","year":"2019","journal-title":"Recent Pat Inflamm. Allergy Drug Discov."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical Tools for Network Meta-Analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One."},{"key":"B5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2165\/11585270-000000000-00000","article-title":"Echinocandin Antifungal Drugs in Fungal Infections: a Comparison","volume":"71","author":"Chen","year":"2011","journal-title":"Drugs."},{"key":"B6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2147\/idr.s51340","article-title":"Profile of Isavuconazole and its Potential in the Treatment of Severe Invasive Fungal Infections","volume":"6","author":"Falci","year":"2013","journal-title":"Infect. Drug Resist."},{"key":"B7","article-title":"Chapter 8: Assessing Risk of Bias in Included Studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions,version 5.1.0","author":"Higgins","year":"2011"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1002\/sim.6188","article-title":"A Design-By-Treatment Interaction Model for Network Meta-Analysis with Random Inconsistency Effects","volume":"33","author":"Jackson","year":"2014","journal-title":"Stat. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/bcp.12150","article-title":"Overview of Methods for Comparing the Efficacies of Drugs in the Absence of Head-To-Head Clinical Trial Data","volume":"77","author":"Kim","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1439-0507.2009.01691.x","article-title":"The Changing Face of Epidemiology of Invasive Fungal Disease in Europe","volume":"52","author":"Lass-Fl\u00f6rl","year":"2009","journal-title":"Mycoses"},{"key":"B11","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1517\/17425255.2012.683859","article-title":"Evaluation of the Pharmacokinetics and Clinical Utility of Isavuconazole for Treatment of Invasive Fungal Infections","volume":"8","author":"Livermore","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/s0140-6736(15)01159-9","article-title":"Isavuconazole Versus Voriconazole for Primary Treatment of Invasive Mould Disease Caused by Aspergillus and Other Filamentous Fungi (SECURE): a Phase 3, Randomised-Controlled, Non-Inferiority Trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1086\/322606","article-title":"Trends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980-1997","volume":"33","author":"McNeil","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: an Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1128\/cmr.00029-06","article-title":"Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin Versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients With Persistent Fever and Neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2147\/tcrm.s47146","article-title":"Application of Caspofungin in China Compared With Amphotericin B and Fluconazole","volume":"10","author":"Zhang","year":"2014","journal-title":"Ther. Clin. Risk Manag."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.697330\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T04:52:33Z","timestamp":1635483153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.697330\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":17,"alternative-id":["10.3389\/fphar.2021.697330"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.697330","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]},"article-number":"697330"}}